13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      c-Jun overexpression in CAR T cells induces exhaustion resistance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          CAR T cells mediate antitumor effects in a small subset of cancer patients 13 , but dysfunction due to T cell exhaustion is an important barrier to progress 46 . To investigate the biology of exhaustion in human T cells expressing CAR receptors, we used a model system employing a tonically signaling CAR, which induces hallmark features of exhaustion 6 . Exhaustion was associated with a profound defect in IL-2 production alongside increased chromatin accessibility of AP-1 transcription factor motifs and overexpression of bZIP and IRF transcription factors that have been implicated in mediating the dysfunctional program present in exhausted cells 710 . Here we demonstrate that engineering CAR T cells to overexpress c-Jun, a canonical AP-1 factor, enhanced expansion potential, increased functional capacity, diminished terminal differentiation and improved antitumor potency in five different in vivo tumor models. We conclude that a functional deficiency in c-Jun mediates dysfunction in exhausted human T cells and that engineering CAR T cells to overexpress c-Jun renders them exhaustion-resistant, thereby addressing a major barrier to progress for this emerging class of therapeutics.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

          Chimeric antigen receptor (CAR) T-cells targeting CD19 mediate potent effects in relapsed/refractory pre-B cell acute lymphoblastic leukemia (B-ALL) but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed on most B-ALL and usually retained following CD19 loss. We report results from a phase I trial testing a novel CD22-CAR in twenty-one children and adults, including 17 previously treated with CD19-directed immunotherapy. Dose dependent anti-leukemic activity was observed with complete remission in 73% (11/15) of patients receiving ≥ 1 × 106 CD22-CART cells/kg, including 5/5 patients with CD19dim/neg B-ALL. Median remission duration was 6 months. Relapses were associated with diminished CD22 site density that likely permitted escape from killing by CD22-CART cells. These results are the first to eastablish the clinical activity of a CD22-CAR in pre-B cell ALL, including in leukemia resistant to anti-CD19 immunotherapy, demonstrating comparable potency to CD19-CART at biologically active doses in B-ALL. They also highlight the critical role played by antigen density in regulating CAR function. (Funded by NCI Intramural Research Program)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

            Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8 T cells (TEX) and improve control of chronic infections and cancer. However, whether blocking PD-1 can reprogram TEX into durable memory T cells (TMEM) is unclear. We found that reinvigoration of TEX in mice by PD-L1 blockade caused minimal memory development. After blockade, reinvigorated TEX became reexhausted if antigen concentration remained high and failed to become TMEM upon antigen clearance. TEX acquired an epigenetic profile distinct from that of effector T cells (TEFF) and TMEM cells that was minimally remodeled after PD-L1 blockade. This finding suggests that TEX are a distinct lineage of CD8 T cells. Nevertheless, PD-1 pathway blockade resulted in transcriptional rewiring and reengagement of effector circuitry in the TEX epigenetic landscape. These data indicate that epigenetic fate inflexibility may limit current immunotherapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumor Antigen Escape from CAR T-cell Therapy

              Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies demonstrate that a common mechanism of resistance to this novel class of therapeutics is the emergence of tumors with loss or downregulation of the target antigen. Antigen loss or antigen-low escape is likely to emerge as an even greater barrier to success in solid tumors, which manifest greater heterogeneity in target antigen expression. Potential approaches to overcome this challenge include engineering CAR T cells to achieve multispecificity and to respond to lower levels of target antigen and more efficient induction of natural antitumor immune responses as a result of CAR-induced inflammation. In this article, we review the evidence to date for antigen escape and downregulation and discuss approaches currently under study to overcome these obstacles.Significance: Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T-cell therapy. Here, we explore their incidence and ways to overcome these obstacles in order to improve clinical outcomes. Cancer Discov; 8(10); 1219-26. ©2018 AACR.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                15 November 2019
                04 December 2019
                December 2019
                04 June 2020
                : 576
                : 7786
                : 293-300
                Affiliations
                [1 ]Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
                [2 ]Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA
                [3 ]Department of Biomedical Data Science, Stanford University, Stanford, CA
                [4 ]Parker Institute for Cancer Immunotherapy, San Francisco, CA
                [5 ]Department of Neurology, Stanford University, Stanford, CA
                [6 ]Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA
                [7 ]Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
                [8 ]Chan Zuckerberg Biohub, San Francisco, CA
                [9 ]Howard Hughes Medical Institute, Stanford University, Stanford, CA
                [10 ]Department of Medicine, Stanford University School of Medicine, Stanford, CA
                Author notes
                [±]

                Current affiliation: Lyell Immunopharma, South San Francisco, CA

                [~]

                Authors contributed equally.

                AUTHOR CONTRIBUTIONS

                R.C.L. cloned the constructs, designed and performed experiments, analyzed data, and wrote the manuscript. E.W.W. and E.S. designed and performed experiments. E.S. performed all immunoblots, immunoprecipitations and GSEAs. D.G., J.G., A.T.S., and H.Y.C. performed and analyzed ATAC-seq. Z.G., C.D.B., and S.R.Q. performed/analyzed single-cell RNA-seq. H.A. and R.J. performed/analyzed bulk RNA-seq. J.L. and V.T. cloned the JUN-mutant and JUN-DD constructs and performed experiments. R.M. cloned the HA-GD2 CAR and created the CD19-low Nalm6. P.X. did animal injections and imaging. S.N. and M.M. performed ChIP-seq experiments and analysis. C.L.M. designed experiments and wrote the manuscript.

                Correspondence: Crystal L Mackall MD, Lorry Lokey Stem Cell Bldg., 265 Campus Drive, Ste 3141A, MC5456, Stanford, CA 94305, 650-725-9670, cmackall@ 123456stanford.edu
                Article
                NIHMS1541323
                10.1038/s41586-019-1805-z
                6944329
                31802004
                e85df88e-b07f-4418-92c2-038295f73e27

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article